NCT05090904View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

November 1, 2022

Study Completion Date

November 1, 2022

Conditions
Cystic Fibrosis
Interventions
DRUG

Brensocatib

Oral tablet

DRUG

Placebo

Oral tablet

Trial Locations (14)

48109

USA023, Ann Arbor

63101

USA002, St Louis

75708

USA003, Tyler

32610-0001

USA001, Gainesville

30912-0004

USA016, Augusta

60025-7645

USA025, Glenview

02115-5724

USA011, Boston

10032-3720

USA022, New York

44106-1716

USA008, Cleveland

44195-0001

USA006, Cleveland

97239-3011

USA018, Portland

29425-8900

USA009, Charleston

37232-0028

USA017, Nashville

75390-7208

USA004, Dallas

All Listed Sponsors
lead

Insmed Incorporated

INDUSTRY

NCT05090904 - A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis | Biotech Hunter | Biotech Hunter